7PBC

Crystal structure of engineered TCR (796) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide

これはPDB形式変換不可エントリーです。

7PBC の概要

• エントリーDOI: 10.2210/pdb7pbc/pdb
• 分子名称: MHC class I antigen, Beta-2-microglobulin, T-cell receptor (TRAV/TRAC), ... (8 entities in total)
• 機能のキーワード: t-cell receptor, human leukocyte antigen, immunoglobulin fold, complex, immune system
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 5
• 化学式量合計: 95298.22

構造登録者

Simister, P.C.,Border, E.C.,Vieira, J.F.,Pumphrey, N.J. (登録日: 2021-08-02, 公開日: 2022-08-03, 最終更新日: 2024-10-09)

主引用文献

Simister, P.C.,Border, E.C.,Vieira, J.F.,Pumphrey, N.J.
Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
J Immunother Cancer, 10:-, 2022

PubMed Abstract: T-cell receptor (TCR) immunotherapy is becoming a viable modality in cancer treatment with efficacy in clinical trials. The safety of patients is paramount, so innovative cell engineering methods are being employed to exploit adaptive immunity while controlling the factors governing antigen receptor (ie, TCR) specificity and cross-reactivity. We recently reported a TCR engineering campaign and selectivity profiling assay (X-scan) targeting a melanoma antigen gene (MAGE)-A10 peptide. This helped to distinguish between two well-performing TCRs based on cross-reactivity potential during preclinical drug evaluation, allowing one to be advanced to T-cell immunotherapeutic clinical trials. Here, we present three-dimensional structural information on those TCRs, highlighting engineering improvements and molecular mechanisms likely underpinning differential selectivity.

PubMed: 35851311
DOI: 10.1136/jitc-2022-004600

実験手法

X-RAY DIFFRACTION (2.04 Å)